SimianX AI LogoSimianX AI

Primärquellen-Eintrag

WesentlichEMA-Stellungnahme

AbbVie: Positives CHMP-Gutachten für RINVOQ bei nicht-segmentaler Vitiligo

CHMP adopted a positive opinion recommending EU approval of upadacitinib 15 mg once daily for adults and adolescents with non-segmental vitiligo. If approved, RINVOQ would become the first systemic therapy specifically indicated for this indication. The European Commission decision is expected in the coming months.

Kernfakten

Eingereicht
29. Juni 2026, 07:00
Ereignis
EMA-Stellungnahme
Richtung
Positiv
Unternehmen
ABBVAbbVie
Asset
upadacitinib
Quelle
Unternehmensmitteilung
Belegstatus
Belegt

Auszug aus der Quelle

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo USA - English USA - English News provided by AbbVie Jun 29, 2026, 03:00 ET Share this article Share to X Share this article Share to X If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs for those living with the chronic, unpredictable autoimmune disease Positive CHMP opinion is supported by data from the Phase 3 Viti-Up clinical studies, in which upadacitinib achieved both co-primary endpoints demonstrating a

Unternehmensmitteilung

Mehr zu diesem Asset